The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer
M J Labonte, P M Wilson, D Yang, W Zhang, R D Ladner, Y Ning, A Gerger, P O Bohanes, L Benhaim, R El-Khoueiry, A El-Khoueiry, H-J Lenz, Melissa LaBonte Wilson
Dive into the research topics of 'The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer'. Together they form a unique fingerprint.